Axsome Therapeutics, Inc. (AXSM) Earnings Call Transcripts
Axsome Therapeutics, Inc.'s Latest Earnings Call - May 1, 2026
In the first quarter of fiscal year 2026, Axsome Therapeutics (AXSM) announced the FDA approval of AUVELITY for treating agitation associated with dementia due to Alzheimer's disease, marking a significant milestone for the company. The approval is expected to address a substantial unmet medical need for over 5 million patients in the U.S. alone. Management highlighted AUVELITY's differentiated efficacy and safety profile, with a significant reduction in agitation symptoms demonstrated in clinical trials. While no specific revenue figures were provided, management indicated strong payer coverage and a comprehensive launch strategy, with expectations for a full commercial launch in June 2026.
Reported metrics
| Metric | Value |
|---|---|
| FDA Approval Date | May 1, 2026 (positive) |
| Patient Population | 5 million (positive) |
| Sales Force Size | 630 representatives (positive) |
| Payer Coverage | 100% (positive) |
| Commercial Launch Date | June 2026 (positive) |
| Reduction in Agitation Symptoms | 14.9 points (positive) |
Guidance from management
Axsome is preparing for a full commercial launch of AUVELITY in June 2026, with expectations for strong market penetration due to comprehensive payer coverage and an experienced sales force. Management did not provide specific revenue guidance but expressed confidence in the product's potential market impact.
What management said
Great. Thank you, Dr. Cummings. And so what we'd like to do now is open the line for question. Now I'll pass it to the operator who will provide the instructions for how to get in the question queue, if that's of interest.
And John, the only thing I'd add is our insurance coverage and the contracts that we've negotiated will support first-line use for the majority of patients. So I think that is in line with Dr. Cummings' view on potential place of treatment.
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape, particularly the off-label use of SSRIs and atypical antipsychotics, which could impact AUVELITY's market share. There were also questions about the potential barriers to patient access due to prior authorization requirements and out-of-pocket costs for non-low-income subsidy Medicare patients.
Main topics on the call
- FDA Approval of AUVELITY — The FDA has approved AUVELITY for treating agitation associated with Alzheimer's disease, which is a first-in-class medicine. CEO Herriot Tabuteau stated, "This approval... marks an important milestone for the millions o...
- Market Opportunity and Launch Strategy — Axsome plans to leverage its existing sales force of approximately 630 representatives to target 68,000 healthcare professionals. The company expects to complete launch preparations in about one month, with a full launch...
- Payer Coverage — Management reported strong payer coverage, with approximately 100% of lives covered in Medicare and Medicaid, and 78% of commercially insured lives. This coverage is expected to facilitate patient access to AUVELITY. Tab...
- Efficacy Data from Clinical Trials — In clinical trials, AUVELITY demonstrated a 14.9-point reduction in agitation symptoms compared to an 11.6-point reduction for placebo. The CEO highlighted that AUVELITY "has demonstrated substantial symptom improvement,...
Read the full Axsome Therapeutics, Inc. transcript (May 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 63 calls on record spanning January 13, 2020 to September 16, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 63 Axsome Therapeutics, Inc. earnings call transcripts on record, spanning January 13, 2020 to September 16, 2026. Based on this history, Axsome Therapeutics, Inc. reports quarterly. The most recent call on file is dated September 16, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AXSM
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 63
- First call
- January 13, 2020
- Most recent
- September 16, 2026
- Reporting cadence
- quarterly